tiprankstipranks
Essex Bio-Technology Limited (HK:1061)
:1061
Hong Kong Market

Essex Bio-Technology (1061) Price & Analysis

Compare
0 Followers

1061 Stock Chart & Stats


---

Financials

Quarterly

Options Prices

Currently, No data available
---

Ownership Overview

1.81%98.17%
Insiders
1.81%
Mutual Funds
― Other Institutional Investors
98.17% Public Companies and
Individual Investors

1061 FAQ

What was Essex Bio-Technology Limited’s price range in the past 12 months?
Essex Bio-Technology Limited lowest stock price was HK$2.14 and its highest was HK$3.99 in the past 12 months.
    What is Essex Bio-Technology Limited’s market cap?
    Essex Bio-Technology Limited’s market cap is HK$2.21B.
      When is Essex Bio-Technology Limited’s upcoming earnings report date?
      Essex Bio-Technology Limited’s upcoming earnings report date is Aug 26, 2025 which is in 146 days.
        How were Essex Bio-Technology Limited’s earnings last quarter?
        Essex Bio-Technology Limited released its earnings results on Mar 26, 2025. The company reported HK$0.264 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.264.
          Is Essex Bio-Technology Limited overvalued?
          According to Wall Street analysts Essex Bio-Technology Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Essex Bio-Technology Limited pay dividends?
            Essex Bio-Technology Limited pays a Annually dividend of HK$0.104 which represents an annual dividend yield of 2.9%. See more information on Essex Bio-Technology Limited dividends here
              What is Essex Bio-Technology Limited’s EPS estimate?
              Essex Bio-Technology Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Essex Bio-Technology Limited have?
              Essex Bio-Technology Limited has 567,076,000 shares outstanding.
                What happened to Essex Bio-Technology Limited’s price movement after its last earnings report?
                Essex Bio-Technology Limited reported an EPS of HK$0.264 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.707%.
                  Which hedge fund is a major shareholder of Essex Bio-Technology Limited?
                  Currently, no hedge funds are holding shares in HK:1061
                  ---

                  Essex Bio-Technology Stock Smart Score

                  8
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  73.56%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  15.18%
                  Trailing 12-Months
                  Asset Growth
                  5.50%
                  Trailing 12-Months

                  Company Description

                  Essex Bio-Technology Limited

                  Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Ping An Insurance Company of China
                  Sino Biopharmaceutical
                  Livzon Pharmaceutical Group
                  Sinopharm Group Co
                  TOM Group
                  Popular Stocks
                  ---
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis